The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: Retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: The RONIN study

Modern Rheumatology

Volumn 21, Issue 4, 2011, Pages 352-358

  Sagawa, Akira ^a  

^a Sagawa Akira Rheumatology Clinic   (Japan)

Author keywords

Interleukin 6; Rheumatoid arthritis; Synovitis; Tocilizumab; Ultrasonography

Indexed keywords

BUCILLAMINE; CORTICOSTEROID; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; TACROLIMUS; TOCILIZUMAB;

ADULT; AGED; ARTICLE; CASE REPORT; CELLULITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOGRAPHY; ELBOW; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMAGING SYSTEM; JAPAN; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAPSE; RETREATMENT; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT OUTCOME; ULTRASOUND; VISUAL ANALOG SCALE; WRIST;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; RECURRENCE; RETREATMENT; SEVERITY OF ILLNESS INDEX; SYNOVITIS; TREATMENT OUTCOME;

EID: 83255161975     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0419-6     Document Type: Article

References (19)

1. Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408-14. (Pubitemid 34664785)
2. Toki H, Momohara S, Tsukahara S, Ikari K. Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration. J Rheumatol. 2008;35:1896-7.
3. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-94. (Pubitemid 351183307)
4. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010;38:82-9.
5. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7. (Pubitemid 47309731)
6. Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Ostergaard M. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003;48:955-62. (Pubitemid 36418237)
7. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 2006;33:31-6. (Pubitemid 43054276)
8. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508-16. (Pubitemid 38530193)
9. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and antiinfliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007;66:253-6. (Pubitemid 46226064)
10. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782-9. (Pubitemid 44955878)
11. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford). 2007;46:1828-34. (Pubitemid 350168300)
12. van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008;27: 1021-8.
13. van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, et al. Sustained effect after lowering highdose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis. 2008;67:1697-701.
14. Miyasaka N, CHANGE Study investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252-62.
15. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403-7. (Pubitemid 40283050)
16. Nishimoto N, Japanese MRA Study Group for RA. Drug free remission after cessation of actemra monotherapy (DREAM STUDY). Ann Rheum Dis. 2010;69[Suppl 3]:98.
17. Nishimoto N, Japanese MRA Study Group for RA. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis at recurrence (RESTORE STUDY). Ann Rheum Dis. 2010;69[Suppl 3]:537.
18. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-9.
19. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53:851-6. (Pubitemid 23077873)